IGF::OT::IGF NEUROPSYCHOLOGICAL ASSESSMENT SYSTEM FOR CANCER PATIENTS

认知能力下降是许多癌症幸存者的主要生活质量问题。这个问题受到 一个特定的个体接受的治疗。不幸的是，研究几乎没有提供什么指导， 基于不利的认知副作用，治疗可能对个体是最好的。为了帮助研究人员填补这个 为了消除信息鸿沟，并为医生和病人提供所需的指导，我们建议制定一个 神经心理学评估系统是专门为癌症患者和幸存者设计的。该系统 移动的，自我管理，并具有最小的实践效果。神经认知内容已被证明对 癌症治疗的微妙认知效应，并适合重复给药。该移动的电池 跨平台，并使用教学视频和语音识别进行自我管理和自动评分。的 来自电池的数据被自动上传到安全服务器用于评分。两个门户网站（一个供临床医生使用， 其他用于研究人员）提供在线订购测试，审查结果，甚至协议定制。克里尔 团队非常有资格通过利用Creare及其 合作者先前已经开发并验证了用于移动的神经认知评估、移动的听力 评估和药物依从性。

Decline in cognitive ability is a major quality-of-life problem for many cancer survivors. This problem is affected by which treatments a particular individual receives. Unfortunately, research has provided little guidance on which treatment may be best for an individual based on unfavorable cognitive side effects. To help researchers fill this information gap, and provide doctors and patients with the guidance they need, we propose to develop a neuropsychological assessment system that is designed specifically for cancer patients and survivors. This system is mobile, self-administered, and has minimal practice effects. The neurocognitive content has been proven sensitive to the subtle cognitive effects of cancer treatment and is appropriate for repeated administration. The mobile battery is cross-platform and uses instruction videos and speech recognition for self-administration and automated scoring. The data from the battery is automatically uploaded to a secure server for scoring. Two web portals (one for clinicians, the other for researchers) offer online ordering of tests, review of results, and even protocol customization. The Creare team is very well qualified to develop and commercialize this system by leveraging software that Creare and its collaborators have previously developed and validated for mobile neurocognitive assessment, mobile hearing assessment, and medication adherence.